Mechanism of action<unk>  is an angiotensin II receptor blocker that shows high affinity for the angiotensin II receptor type 1 (AT1), with a binding affinity 3000 times greater for AT1 than AT2. In addition to blocking the renin–angiotensin system,<unk>  acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. It is believed that<unk> 's dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease (CVD).<unk> 's activity at the peroxisome proliferator-activated receptor delta (PPAR-δ) receptor has prompted speculation around its potential as a sport doping agent as an alternative to GW 501516.<unk>  activates PPAR-δ receptors in several tissues. Also,<unk>  has a PPAR-γ agonist activity. Pharmacokinetics The substance is quickly but to varying degrees absorbed from the gut. The average bioavailability is about 50% (42–100%). Food intake has no clinically relevant influence on the kinetics of<unk> . Plasma protein binding is over 99.5%, mainly to albumin and alpha-1-acid glycoprotein. It has the longest half-life of any angiotensin II receptor blocker (ARB) (24 hours) and the largest volume of distribution among ARBs (500 liters). Less than 3% of<unk>  is inactivated by glucuronidation in the liver, and over 97% is eliminated in unchanged form via bile and faeces.
Telmisartan
Losartan
Olmesartan
Cyclothiazide
Valsartan
Azilsartan
Irbesartan
Chlorothiazide